Facilitated By

San Antonio Medical Foundation

A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial To Evaluate The Effect Of Ticagrelor 90 Mg Twice Daily On The Incidence Of Cardiovascular Death, Myocardial Infarction Or Stroke In Patients With Type 2 Diabetes Mellitus

Principal Investigator(s)
Email for information
Funded by
GENEVA
Research Start Date
Status
Active

The primary objective of this study is to compare the effect of long-term treatment with ticagrelor 90 mg twice daily vs. placebo for the prevention of major cardiovascular (CV) events in patients with Type 2 Diabetes Mellitus (T2DM) at high risk of CV events, but without a medical history of previous MI or stroke.

Clinical Care
Cardiovascular
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.